Characterizing upper limb function in the context of activities of daily living in CLN3 disease

被引:3
|
作者
Hildenbrand, Hanna [1 ]
Wickstrom, Jordan [1 ]
Parks, Rebecca [1 ]
Zampieri, Cris [1 ]
Nguyen, Thuy-Tien [1 ]
Thurm, Audrey [2 ]
Jenkins, Kisha [3 ]
Alter, Katharine E. [1 ]
Matsubara, Jesse [1 ]
Hammond, Dylan [3 ]
Soldatos, Ariane [4 ]
Porter, Forbes D. [3 ]
Dang Do, An N. [3 ]
机构
[1] NIH, Dept Rehabil Med, Ctr Clin, Bethesda, MD 20892 USA
[2] NIMH, Neurodev & Behav Phenotyping Serv, NIH, Bethesda, MD 20892 USA
[3] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Off Clin Director, NIH, 10 Ctr Dr,Room 2-5132, Bethesda, MD 20892 USA
[4] NINDS, Pediat Neurol Consultat Serv, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA
关键词
Batten; motor function; neuronal ceroid lipofuscinoses; occupational therapy; rehabilitation; LIPOFUSCINOSIS BATTEN-DISEASE; TEST-RETEST RELIABILITY; JEBSEN TAYLOR TEST; HAND FUNCTION; DISABILITY INVENTORY; PEDIATRIC EVALUATION; PHYSICAL-ACTIVITY; VISUAL IMPAIRMENTS; CHILDREN; PERFORMANCE;
D O I
10.1002/ajmg.a.62114
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
In CLN3 disease, impairments in motor function are frequently reported to have later onset compared to visual and cognitive decline, but upper limb motor function has yet to be explored in this population. In a cohort of 22 individuals with CLN3, we used a novel application of multiple measures to (1) characterize motor function, particularly of the upper limbs, in activities of daily living (ADLs), and (2) explore associations between motor function and age as well as visual ability, disease severity, and cognitive function, as evaluated by the Unified Batten Disease Rating Scale (UBDRS), a validated CLN3 disease measure. ADLs that required coordination, speed, and fine motor control were particularly challenging for children with CLN3 based on item-level performance across direct assessments (Jebsen-Taylor Hand Function Test [JTHFT] and MyoSet Tools) and caregiver reports (Pediatric Evaluation of Disability Inventory-Computer Adaptive Testing [PEDI-CAT] and Patient-Reported Outcomes Measurement Information System [PROMIS] Pediatric Upper Extremity). Poorer visual ability, disease severity, and cognitive function were associated with worse performance on these measures, whereas age had limited impact. These findings support the need for children with CLN3 to receive skilled clinical evaluation and treatment tailored to their individual needs, particularly in the context of ADLs, as their symptom profile progresses.
引用
收藏
页码:1399 / 1413
页数:15
相关论文
共 50 条
  • [41] Exogenous Flupirtine as Potential Treatment for CLN3 Disease
    Maalouf, Katia
    Makoukji, Joelle
    Saab, Sara
    Makhoul, Nadine J.
    Carmona, Angelica V.
    Kinarivala, Nihar
    Ghanem, Noel
    Trippier, Paul C.
    Boustany, Rose-Mary
    CELLS, 2020, 9 (08) : 1 - 18
  • [42] Toward the function of CLN3 protein: A proteomic approach.
    Wisniewski, KE
    Walus, M
    Kida, E
    Golabek, AA
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2004, 63 (05): : 520 - 520
  • [43] Neurodegeneration and Epilepsy in a Zebrafish Model of CLN3 Disease (Batten Disease)
    Wager, Kim
    Zdebik, Anselm A.
    Fu, Sonia
    Cooper, Jonathan D.
    Harvey, Robert J.
    Russell, Claire
    PLOS ONE, 2016, 11 (06):
  • [44] A proposed staging system for CLN3 disease (juvenile Batten disease)
    Mink, Jonathan W.
    Williams, Justin D.
    Augustine, Erika F.
    MOLECULAR GENETICS AND METABOLISM, 2018, 123 (02) : S96 - S96
  • [45] The CLN3 Disease Staging System (CLN3SS): A tool for stratification based on disease severity
    Masten, Margaux C.
    Williams, Justin D.
    Augustine, Erika F.
    Vermilion, Jennifer
    Adams, Heather R.
    Vierhile, Amy
    Thatcher, Alyssa
    Marshall, Frederick J.
    Mink, Jonathan W.
    MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : S106 - S106
  • [46] Virtual Activities of Daily Living for Recovery of Upper Extremity Motor Function
    Adams, Richard J.
    Lichter, Matthew D.
    Ellington, Allison
    White, Marga
    Armstead, Kate
    Patrie, James T.
    Diamond, Paul T.
    IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING, 2018, 26 (01) : 252 - 260
  • [47] Immunochemical localization of the Batten disease (CLN3) protein in retina
    Katz, ML
    Gao, CL
    Prabhakaram, M
    Shibuya, H
    Liu, PC
    Johnson, GS
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1997, 38 (11) : 2375 - 2386
  • [48] Developing A Staging System for Juvenile Batten Disease (CLN3 Disease)
    Williams, J.
    Augustine, E.
    Mink, J.
    ANNALS OF NEUROLOGY, 2017, 82 : S307 - S307
  • [49] The natural history of juvenile Batten disease (JNCL; CLN3 disease)
    Mink, Jonathan
    Augustine, Erika F.
    Marshall, Frederick J.
    Adams, Heather R.
    Kwon, Jennifer M.
    Vierhile, Amy
    de Blieck, Elisabeth A.
    MOLECULAR GENETICS AND METABOLISM, 2013, 108 (02) : S66 - S66
  • [50] Disease progression in JNCL: Quantification and relation to CLN3 genotype
    Kwon, JM
    Rothberg, PG
    Marshall, FJ
    De Blieck, EA
    Adams, H
    Vierhile, A
    Stachowski, EK
    Pearce, DA
    Mink, JW
    NEUROLOGY, 2006, 66 (05) : 271 - 271